Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific and Middle East: 1,929 cases from 40 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- Purdue Pharma L.P. €4.75bn 78 % · 1 case
- Teva Pharmaceutical Industries (Teva-Gruppe) €462.6m 8 % · 1 case
- Teva Pharmaceuticals USA, Inc. und Teva Neuroscience, Inc. €411.6m 7 % · 1 case
- Gilead Sciences, Inc. €177.8m 3 % · 1 case
- Pfizer Inc. (für die Tochter Biohaven Pharmaceutical Holding Company Ltd.) €57.1m 1 % · 1 case
- Anonymised companies €49.1m 1 % · 4 cases
- Novamont S.p.A., Eni S.p.A. €32.1m 1 % · 1 case
- Dompé U.S. Inc. €27.5m 0 % · 1 case
- Vifor Pharma UK Limited u. a. (CSL-Konzern) €27.4m 0 % · 1 case
- The Chemours Company; The Chemours Company FC, LLC €19.8m 0 % · 1 case
- 26 more€52.2m
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q4 2023 | 0 | – |
| Q1 2024 | 0 | – |
| Q2 2024 | 0 | – |
| Q3 2024 | 0 | – |
| Q4 2024 | 0 | – |
| Q1 2025 | 0 | – |
| Q2 2025 | 1 | €1m |
| Q3 2025 | 0 | – |
| Q4 2025 | 0 | – |
| Q1 2026 | 0 | – |
| Q2 2026 | 0 | – |
| Q3 2026 | 0 | – |
| Q4 2026 | 0 | – |
1 case
24 Jun 2025 Grifols, S.A.CNMV: €1m fine on Grifols for flawed financial reports and performance measures €1m
The Comisión Nacional del Mercado de Valores (CNMV, Spanish securities market supervisor) imposed two fines totalling 1,000,000 EUR on Grifols: 800,000 EUR because the consolidated financial statements for 2021 to 2023 and the 2023 half-year report contained inaccurate or incomplete information under IFRS, and 200,000 EUR for misleading information on the calculation of alternative performance measures (APMs) in the management reports. The company waived administrative appeals.
Alternative performance measures must be calculated transparently and traceably; the issuer is liable for incorrect financial information.
Accuracy of financial reports and alternative performance measures
- Authority / court
- Comisión Nacional del Mercado de Valores (CNMV)
- Area of law
- Capital markets and financial supervision · Disclosure and reporting obligations
- Legal basis
- Art. 282.1.b) und Art. 292.1.f) Ley 6/2023 de los Mercados de Valores y de los Servicios de Inversión
- Action
- Fine
- Status of proceedings
- unknown
- Sector
- Chemicals and pharmaceuticals
- Employees
- 10,000 or more
- Liability of senior managers
- Measures against individuals are not reported here.
- Published
- 6 Aug 2025
- BOE-A-2025-16320: Resolución de 24 de julio de 2025 de la CNMV (Grifols, SA) Official register or notice
- CNMV, Registro público de sanciones impuestas por la CNMV Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Direct link